TissueInsight®

Scientific Advisors

Flagship Biosciences scientific advisors are nationally and internationally recognized pathologists and oncologists who are experts in cancer care.  These professionals make significant contributions in clinical research and they hold faculty appointments at leading US medical schools and cancer centers.

Richard J. Cote, M.D.,  FRCPath, FCAP

The Edward Mallinckrodt Professor and Chair and Professor of the Department of Pathology and Immunology, Washington University in St. Louis School of Medicine; Pathologist in Chief, Barnes Jewish Hospital

Dr. Cote is the Edward Mallinckrodt Professor and Chair and Professor of the Department of Pathology and Immunology at Washington University in St. Louis School of Medicine, and the Pathologist in Chief at Barnes Jewish Hospital. Prior to this he was the Joseph R. Coulter Jr. Chair of the Department of Pathology, Professor of Biochemistry and Molecular Biology, and Founding Director of the Dr. John T. Macdonald Foundation Biomedical Nanotechnology Institute at the University of Miami Miller School of Medicine. He is a board-certified Pathologist, serving over 25 years in senior academic, consultative, and director/clinical roles with leading universities, hospitals and healthcare enterprises. Dr. Cote obtained degrees in chemistry and biology at the University of California at Irvine and received his medical degree from the University of Chicago – Pritzker School of Medicine. He completed his residency at New York Hospital – Cornell University Medical College. His training included a clinical fellowship in pathology at Memorial Sloan-Kettering Cancer Center, a research fellowship in Human Tumor Immunology at Memorial Sloan-Kettering Cancer Center and a fellowship in Molecular Pathology at New York University School of Medicine. Prior to 2009, he was Professor, Departments of Pathology and Urology; Director, Genitourinary Cancer Program; Director, Laboratory of Immunology and Molecular Pathology; and Director of the USC Biomedical Nanoscience Initiative at the University of Southern California Keck School of Medicine.

David Sidransky, M.D.

Director of the Head and Neck Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University; Professor of Oncology, Otolaryngology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology, Johns Hopkins University and Hospital; Chairman of the Board, Advaxis Inc.; Chairman of the Board, Ayala Pharmaceuticals

Dr. Sidransky is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. He serves as the Director of the Head and Neck Cancer Research Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. He is a Professor of Oncology, Otolaryngology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at John Hopkins University and Hospital. Dr. Sidransky has written over 550 peer-reviewed publications and has contributed to more than 60 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. He has been the recipient of many awards and honors, including the 1997 Sarstedt International prize from the German Society of Clinical Chemistry, 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians and the 2004 Hinda Rosenthal Award and 2017 Team Award presented by the American Association of Cancer Research. He is Chairman of the Board of Advaxis Inc. and Ayala Pharmaceuticals and is a lead director at Champions Oncology and Galmed and is also on the board of directors of Orgenesis.  In addition, Dr. Sidransky served as Director of American Association for Cancer Research from 2005 to 2008. Dr. Sidransky received his B.A. from Brandeis University and his M.D. from the Baylor College of Medicine.

Joseph Sirintrapun, M.D.

Director of Pathology Informatics at Memorial Sloan Kettering Cancer Center (MSKCC); Associate Attending and member of the Warren Alpert Center for Computational Pathology at MSKCC; 2021 President of the Association for Pathology Informatics (API) 

Dr. Sirintrapun’s efforts are in data and systems engineering as it relates to digital and computational pathology. He works towards a better understanding of the cognitive and social impacts of technology on clinical practice, and particularly on “operationalization” or the translation of innovations in digital pathology and computational pathology to practice. Dr. Sirintrapun is also passionately engaged in cultivating a medical and technological workforce to propel pathology informatics and computational pathology into the future. Dr. Sirintrapun is board certified in Anatomic and Clinical Pathology and Clinical Informatics. In addition to his work in informatics, he practices surgical pathology specializing in genitourinary tumors.